Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 10/20 | 0.61 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24368215 | 0.99 | CTSL (0.63) | CTSLUSP30CTSSCTSKPSMB5 | |
| SCHEMBL24368216 | 0.99 | CTSL (0.63) | CTSLUSP30CTSSCTSKPSMB5 | |
| SCHEMBL24368217 | 0.97 | CTSL (0.60) | CTSLUSP30CTSSCTSKPSMB5 | |
| SCHEMBL24368213 | 0.97 | CTSL (0.60) | CTSLUSP30CTSSCTSKPSMB5 | |
| SCHEMBL28530796 | 0.96 | CTSL (0.61) | CTSLUSP30CTSSCTSKPSMB5 | |
| SCHEMBL24368196 | 0.96 | CTSL (0.61) | CTSLUSP30CTSSCTSKPSMB5 | |
| SCHEMBL24368208 | 0.94 | CTSL (0.52) | CTSLUSP30CTSSCTSKCA2 | |
| Aurantiamide Acetate SCHEMBL4357298 | 0.92 | CTSL (0.71) | CTSLCTSSCTSKPSMB5PIN1 | |
| Aurantiamide Acetate SCHEMBL31084254 | 0.92 | CTSL (0.71) | CTSLCTSSCTSKPSMB5PIN1 | |
| Aurantiamide Acetate SCHEMBL30532189 | 0.92 | CTSL (0.71) | CTSLCTSSCTSKPSMB5PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112500308-B | Golden amide alcohol ester and fluorinated derivative thereof, and preparation method and application thereof | 澳门科技大学 | 2023-10-03 | — | — | CN | disclosed |
| US-11377418-B2 | Compounds and methods for treating influenza | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2022-07-05 | — | — | US | disclosed |
| US-20220127220-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127220-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | H1-3, HRH3, H1-4 | CTSL 1708/4885USP30 2321/4885CTSS 1088/4885 |
| US-11377418-B2 | Compounds and methods for treating influenza | H1-3, HRH3, H1-4 | CTSL 1708/4885USP30 2321/4885CTSS 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.